This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Knox, J. J. Articles by Moore, M. J. Search for Related Content PubMed PubMed Citation Articles by Knox, J. J. Articles by Moore, M. J. Social Bookmarking                            What's this?

Combining Gemcitabine and Capecitabine in Patients With Advanced Biliary Cancer: A Phase II Trial

From the Departments of Hematology, Medical Oncology, and Biostatistics, Princess Margaret Hospital/University Health Network; and Department of Medicine, University of Toronto

Address reprint requests to J. Knox, MD, Princess Margaret Hospital, 5-218, 610 University Ave, Toronto, Ontario, Canada, M5G 2M9; e-mail: jennifer.knox{at}uhn.on.ca

PURPOSE: Biliary cancer has a poor prognosis, and chemotherapy has had little impact. The objectives of this trial were to determine the response rate, time to disease progression, survival, and safety profile of the combination of gemcitabine and capecitabine (GemCap) in patients with advanced biliary cancer.

PATIENTS AND METHODS: Eligible patients had pathologically proven, locally advanced or metastatic adenocarcinoma arising from the intra- and extrahepatic bile ducts or gallbladder with no prior chemotherapy. Patients were treated on a 3-week cycle consisting of capecitabine at 650 mg/m² orally twice a day for 14 days and gemcitabine at a fixed dose of 1,000 mg/m² intravenously over 30 minutes on days 1 and 8.

RESULTS: Forty-five patients were enrolled between July 2001 and January 2004. Fifty-three percent of patients had cholangiocarcinoma, 47% had gallbladder cancer, and 89% had metastatic disease. The overall objective response rate was 31%, with an additional 42% of patients with stable disease, for a disease control rate of 73%. The median overall survival time was 14 months (95% CI, 7.3 months to not available), and the median progression-free survival time was 7 months (95% CI, 4.6 to 11.8 months). This chemotherapy combination was generally well tolerated. Transient neutropenia, thrombocytopenia, fatigue, and hand-foot syndrome were commonly observed but were easily managed without discontinuing further treatment.

CONCLUSION: The significant antitumor activity combined with a mild toxicity profile seen in this study argue that GemCap chemotherapy may benefit patients with advanced biliary cancer. This regimen warrants further evaluation in a randomized study with survival and quality of life end points.

Supported in part by Hoffman La Roche and Eli Lilly, Canada.

Presented in part at the 2004 Gastrointestinal Cancers Symposium: Current Status and Future Directions for Prevention and Management, San Francisco, CA, January 22-24, 2004; and at the 12th European Cancer Conference, Copenhagen, Denmark, September 21-25, 2003.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. Palmieri, G. Merola, P. Federico, L. Petillo, M. Marino, M. Lalle, M. Milella, A. Ceribelli, L. Montella, C. Merola, et al. Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs) Ann. Onc., October 30, 2009; (2009) mdp483v1. [Abstract] [Full Text] [PDF]

				Y.-i. Yamashita, A. Taketomi, S. Itoh, N. Harimoto, E. Tsujita, K. Sugimachi, T. Gion, and Y. Maehara Phase II Trial of Gemcitabine Combined with 5-fluorouracil and Cisplatin (GFP) Chemotherapy in Patients with Advanced Biliary Tree Cancers Jpn. J. Clin. Oncol., September 20, 2009; (2009) hyp119v1. [Abstract] [Full Text] [PDF]

				W. R. Jarnagin, L. H. Schwartz, D. H. Gultekin, M. Gonen, D. Haviland, J. Shia, M. D'Angelica, Y. Fong, R. DeMatteo, A. Tse, et al. Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival Ann. Onc., September 1, 2009; 20(9): 1589 - 1595. [Abstract] [Full Text] [PDF]

				B. R. Tan, W. S. Brenner, J. Picus, S. Marsh, F. Gao, C. Fournier, P. M. Fracasso, J. James, J. L. Yen-Revollo, and H. L. Mcleod Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies Ann. Onc., October 1, 2008; 19(10): 1742 - 1748. [Abstract] [Full Text] [PDF]

				D. Koeberle, P. Saletti, M. Borner, D. Gerber, D. Dietrich, C. B. Caspar, W. Mingrone, K. Beretta, F. Strasser, T. Ruhstaller, et al. Patient-Reported Outcomes of Patients With Advanced Biliary Tract Cancers Receiving Gemcitabine Plus Capecitabine: A Multicenter, Phase II Trial of the Swiss Group for Clinical Cancer Research J. Clin. Oncol., August 1, 2008; 26(22): 3702 - 3708. [Abstract] [Full Text] [PDF]

				A. F. Hezel and A. X. Zhu Systemic Therapy for Biliary Tract Cancers Oncologist, April 1, 2008; 13(4): 415 - 423. [Abstract] [Full Text] [PDF]

				R. V. Tse, M. Hawkins, G. Lockwood, J. J. Kim, B. Cummings, J. Knox, M. Sherman, and L. A. Dawson Phase I Study of Individualized Stereotactic Body Radiotherapy for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma J. Clin. Oncol., February 1, 2008; 26(4): 657 - 664. [Abstract] [Full Text] [PDF]

				Y. J. Kim, S.-A. Im, H. G. Kim, S. Y. Oh, K. W. Lee, I. S. Choi, D. Y. Oh, S. H. Lee, J. H. Kim, D. W. Kim, et al. A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer Ann. Onc., January 1, 2008; 19(1): 99 - 103. [Abstract] [Full Text] [PDF]

				N. Yonemoto, J. Furuse, T. Okusaka, K. Yamao, A. Funakoshi, S. Ohkawa, N. Boku, K. Tanaka, M. Nagase, H. Saisho, et al. A Multi-center Retrospective Analysis of Survival Benefits of Chemotherapy for Unresectable Biliary Tract Cancer Jpn. J. Clin. Oncol., November 1, 2007; 37(11): 843 - 851. [Abstract] [Full Text] [PDF]

				S. R. Alberts, G. J. Gores, G. P. Kim, L. R. Roberts, M. L. Kendrick, C. B. Rosen, S. T. Chari, and J. A. Martenson Treatment Options for Hepatobiliary and Pancreatic Cancer Mayo Clin. Proc., May 1, 2007; 82(5): 628 - 637. [Abstract] [Full Text] [PDF]

				J. Furuse, T. Okusaka, A. Funakoshi, K. Yamao, M. Nagase, H. Ishii, K. Nakachi, H. Ueno, M. Ikeda, C. Morizane, et al. Early Phase II Study of Uracil-Tegafur Plus Doxorubicin in Patients with Unresectable Advanced Biliary Tract Cancer Jpn. J. Clin. Oncol., September 1, 2006; 36(9): 552 - 556. [Abstract] [Full Text] [PDF]

				P. A. Philip, M. R. Mahoney, C. Allmer, J. Thomas, H. C. Pitot, G. Kim, R. C. Donehower, T. Fitch, J. Picus, and C. Erlichman Phase II Study of Erlotinib in Patients With Advanced Biliary Cancer J. Clin. Oncol., July 1, 2006; 24(19): 3069 - 3074. [Abstract] [Full Text] [PDF]

				J. Gallardo, B. Rubio, L. Villanueva, and O. Barajas Gallbladder Cancer, a Different Disease that Needs Individual Trials J. Clin. Oncol., October 20, 2005; 23(30): 7753 - 7754. [Full Text] [PDF]

				J. J. Knox In Reply J. Clin. Oncol., October 20, 2005; 23(30): 7754 - 7755. [Full Text] [PDF]